Synthesis, Anti-Inflammatory Activities, and Molecular Docking Study of Novel Pyxinol Derivatives as Inhibitors of NF-κB Activation
Molecules · 10.04.2024 · 29 (8) · 1711
DOI: 10.3390/molecules29081711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 10.04.2024. Verfasst von Shuai Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of…. Hauptthemen laut MEDLINE: Molecular Docking Simulation, NF-kappa B, Anti-Inflammatory Agents, Nitric Oxide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Shandong Provincial Natural Science Foundation.
Abstract (Originalsprache)
Pyxinol, an active metabolite of ginsenosides in human hepatocytes, exhibits various pharmacological activities. Here, a series of C-3 modified pyxinol derivatives was designed and virtually screened by molecular docking with the key inflammation-related proteins of the nuclear factor kappa B (NF-κB) pathway. Some of the novel derivatives were synthesized to assess their effects in inhibiting the production of nitric oxide (NO) and mitochondrial reactive oxygen species (MtROS) in lipopolysaccharide-triggered RAW264.7 cells. Derivative 2c exhibited the highest NO and MtROS inhibitory activities with low cytotoxicity. Furthermore, 2c decreased the protein levels of interleukin 1β, tumor necrosis factor α, inducible nitric oxide synthase, and cyclooxygenase 2 and suppressed the activation of NF-κB signaling. Cellular thermal shift assays indicated that 2c could directly bind with p65 and p50 in situ. Molecular docking revealed that 2c’s binding to the p65–p50 heterodimer and p50 homodimer was close to their DNA binding sites. In summary, pyxinol derivatives possess potential for development as NF-κB inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Minis…
ORCID-Profile: Gangqiang Yang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Shandong Provincial Natural Science Foundation
- Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province, and the Students’ Innovation and Entrepreneurship Traini…
Zitieren
APA
Tan, S., Zou, Z., Luan, X., Chen, C., Li, S., Zhang, Z., Quan, M., Li, X., Zhu, W., & Yang, G. (2024). Synthesis, Anti-Inflammatory Activities, and Molecular Docking Study of Novel Pyxinol Derivatives as Inhibitors of NF-κB Activation. Molecules, 29(8), 1711. https://doi.org/10.3390/molecules29081711
Vancouver
Tan S, Zou Z, Luan X, Chen C, Li S, Zhang Z, et al. Synthesis, Anti-Inflammatory Activities, and Molecular Docking Study of Novel Pyxinol Derivatives as Inhibitors of NF-κB Activation. Molecules. 2024;29(8):1711. doi:10.3390/molecules29081711
BibTeX
@article{Tan2024,
author = {Tan, Shuai and Zou, Zongji and Luan, Xuwen and Chen, Cheng and Li, Shuang and Zhang, Zhen and Quan, Mengran and Li, Xiang and Zhu, Wei and Yang, Gangqiang},
title = {Synthesis, Anti-Inflammatory Activities, and Molecular Docking Study of Novel Pyxinol Derivatives as Inhibitors of NF-κB Activation},
journal = {Molecules},
year = {2024},
volume = {29},
number = {8},
pages = {1711},
doi = {10.3390/molecules29081711}
}
EUVIMED